Trends in the Nontuberculous Mycobacterial Disease Mortality Rate in Japan: A Nationwide Observational Study, 1997–2016 by Harada, Ko et al.
1 
Major Article 
Trends in the nontuberculous mycobacterial disease mortality rate in Japan: A 
nationwide observational study, 1997-2016 
Ko Harada1, Hideharu Hagiya1, Tomoko Funahashi2, Toshihiro Koyama3, Mitsunobu R. 
Kano2, Fumio Otsuka1 
1Department of General Medicine, Okayama University Graduate School of Medicine, 
Dentistry and Pharmaceutical Sciences, Okayama, Japan; and 2Department of 
Pharmaceutical Biomedicine, Okayama University Graduate School of Interdisciplinary 
Science and Engineering in Health Systems, Okayama, Japan;  
and 3Department of Pharmaceutical Biomedicine, Okayama University Graduate School of 
Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan. 
Key points 
This study assessed the national trends in mortality due to nontuberculous mycobacterial 
(NTM) disease in Japan from 1997 to 2016. The crude and age-adjusted NTM mortality rates 
increased during this period, particularly among females aged ≥80 years. 
Key words: nontuberculous mycobacteria; trend analysis 
Running title: 
Trends in NTM mortality in Japan 
Corresponding author: 
Hideharu Hagiya, M.D., Ph.D. 
Full Manuscript in .doc format only [no PDFs]
2 
Department of General Medicine,  
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences 




Alternate corresponding author: 
Ko Harada, M.D. 
Department of General Medicine,  
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences 






Background: The incidence of nontuberculous mycobacterial (NTM) infections has been 
increasing worldwide, becoming a significant healthcare burden especially among elderly 
people. This study aimed to evaluate the trends in NTM-associated mortality in Japan. 
Methods: This study used vital statistics data and data on all NTM-associated deaths 
(N=18,814) among individuals aged ≥40 years in Japan from 1997 to 2016. We calculated the 
crude and age-adjusted mortality rates by age and sex and used joinpoint regression to 
analyze trends and estimate the average annual percentage change (AAPC). We compared 
crude NTM- and tuberculosis (TB)-associated mortality rates by sex. 
Results: The overall crude annual mortality rate increased from 0.63/100,000/year in 1997 to 
1.93/100,000/year in 2016 and was the highest among individuals aged 80–84 years. The 
AAPC of the crude mortality rates among males of all ages and females aged 40–59 years 
were stable but increased among females aged 60–79 years (3.5%, 95% confidence interval 
[CI]: 2.8–4.3%) and ≥80 years (4.3%, 95% CI: 3.7–4.9%). Among males, the age-adjusted 
mortality rates did not show a significant trend, while among females, the rates increased 
over the study period (AAPC: 4.6%, 95% CI: 2.7–6.6%). In females, the crude 
NTM-associated mortality rate exceeded the TB mortality rate in 2014, 2015, and 2016. 
Conclusions: NTM mortality increased in Japan between 1997 and 2016, especially among 
the elderly female population. Given the increasing NTM-associated mortality and 




Nontuberculous mycobacteria (NTM) are mycobacteria other than Mycobacterium 
tuberculosis and special auxotrophs such as Mycobacterium leprae, and currently include 
more than 180 species [1]. NTM are ubiquitous environmental bacteria, that are present in 
soil and water sources [2]; among them, Mycobacterium avium complex (MAC), which 
includes M. avium, M. intracellulare, and M. chimaera, is the most common cause of NTM 
diseases worldwide, including Japan [3, 4]. Pathogenic NTM can infect humans as a result of 
ingestion, inhalation, and dermal contact from the environment, causing a wide variety of 
diseases [5]. Although NTM can invade lymph nodes, joints, skin, and soft tissues, they most 
frequently cause pulmonary lesions [5]. NTM pulmonary disease (NTM-PD) has two main 
presentations. The first presentation is a fibrocavitary disease, that occurs in patients with 
pre-existing pulmonary diseases, including chronic obstructive pulmonary disease or 
bronchiectasis. The second manifestation is a nodular bronchiectasis of the lingula and 
middle lobe, that tends to affect middle-aged and elderly women [6, 7]. 
The incidence of NTM infection has been increasing worldwide in recent years. During the 
past decade, the annual NTM disease incidence rates (per 100,000) in developed countries 
were as follows: 0.72–0.74 in France [8], 0.9–2.9 in the United Kingdom [9], 2.7–5.6 in the 
United States [10, 11], and 2.2–3.2 in Australia [12]. The increasing NTM disease incidence 
is placing a significant burden on healthcare systems [13, 14]. In Japan, which has a rapidly 
aging population, the reported incidence rates are higher than those of other developed 
countries. For instance, the annual incidence of NTM-PD in Nagasaki Prefecture was >10.0 
per 100,000 population in 2008–2009 [15]. A large, laboratory-based study that used data 
from 4,710 Japanese institutions, revealed that the incidence rate of NTM-PD was 24.0 per 
100,000 population in 2012–2013 [3]. Additionally, a national cross-sectional study based on 
health insurance claims data revealed an incidence rate of NTM-PD of 29.0 per 100,000 
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population in Japan in 2011, which was among the highest worldwide [16]. Another study, 
that included 551 medical facilities certified by the Japanese Respiratory Society, revealed an 
NTM-PD incidence rate of 14.7 per 100,000 population in Japan in 2014; this was a 2.6-fold 
increase since 2007 [17]. 
Elderly people are more susceptible to NTM disease, and advanced age is an important risk 
factor [10, 18]. Since Japan has one of the most rapidly aging populations in the world, it is 
possible that the mortality rate owing to NTM disease has been increasing. Although 
evaluating longitudinal national trends in NTM-associated mortality rates is essential for 
effective health policy administration, there have been no previous reports on the long-term 
trends in NTM-associated mortality rates in Japan. This study, therefore, aimed to examine 
current trends in NTM-associated mortality. 
Materials and methods 
Data source 
Death certificates in Japan are comprehensively collected and saved as computerized files 
after being completed by medical doctors. The data files including patient’s basic information 
are publicly available after anonymization. We examined the Japanese Vital Statistics data 
from 1997 to 2016, collected by the Japanese Ministry of Health, Labour and Welfare, which 
uses the International Classification of Diseases, 10th revision (ICD-10) to code the 
underlying causes of death [19]. NTM-associated mortality was defined using the ICD-10 
codes A31 (A31.0, A31.1, A31.8, and A31.9), namely, “infection due to other mycobacteria,” 
based on previous studies [20, 21]. Data on NTM-associated mortality analyzed in the present 
study were those recorded as the underlying cause of death in the death certificate, as 
performed in the previous study [21]. Data of patients aged ≥40 years were stratified by age 
and sex to calculate crude and age-adjusted mortality rates per 100,000 population. The age 
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was categorized as follows: 40–59 years, 60–79 years, and ≥80 years. All patients aged <40 
years were excluded from the analysis owing to the small number of deaths in this age 
category. For comparison, we also examined tuberculosis (TB)-associated deaths among 
patients aged ≥40 years during the same period as the underlying cause of death (ICD–10 
codes A15–A19). 
Statistical analyses and data processing 
To estimate the trends in crude and age-adjusted mortality rates, a joinpoint regression model 
was applied using the Joinpoint Regression Program, version 4.7.0.0, February 2019 
(Statistical Research and Applications Branch, National Cancer Institute, USA). The annual 
percentage changes (APCs) between trend-change points were determined with 95% 
confidence intervals (CI). We used the direct age-standardization method to calculate 
age-adjusted rates of NTM-associated mortality using the Japanese population in 1997 as the 
standard population, expressed per 100,000 population, with 5-year age groups. To compare 
differences in mortality trends among population subgroups, we estimated the average annual 
percentage change (AAPC) for the entire period. A p-value <0.05 was defined as the level at 
which the slope was statistically significantly different from zero. 
Ethics approval 
This study used data published by the Japanese Ministry of Health, Labour and Welfare and 
the Statistics Bureau of the Ministry of Internal Affairs and Communications. Ethics approval 
was obtained by the institutional review board of Okayama University Hospital (No. 
1910-009). The requirement for informed consent was waived, as the study was a 
retrospective analysis of routinely collected data. 
7 
Results 
Number of NTM-associated deaths 
In total, 18,791 NTM-associated deaths occurred over the 20-year study period. The annual 
number of deaths by sex is shown in Fig. 1. During the study period, the total number of 
deaths per year increased from 402 in 1997 to 1,487 in 2016. Although the number of 
NTM-associated deaths among males and females was similar in 1997 (183 and 219, 
respectively), the number of deaths among females were approximately double that of males 
in 2016 (478 and 1,009, respectively). The numbers of NTM-associated deaths by 5-year age 
groups are shown in Fig. 2. The number of NTM-associated deaths increased from 45 years 
of age, reaching its peak in both sexes in the 80–84-year age group. 
Trends in the crude NTM mortality rates by age and sex 
Fig. 3 summarizes the crude mortality rates of NTM-associated deaths among patients aged 
≥40 years, by 20-year age groups and sex. The detailed results for each age group are 
provided in Supplementary Table 1. The overall crude annual mortality rate per 100,000 
population increased from 0.63 in 1997 to 1.93 in 2016. The crude mortality rates were 
higher in both sexes of the older age groups. The results of the joinpoint regression analysis 
of the crude mortality rates by 20-year age groups are shown in Table 1. In males, AAPCs for 
the entire period of the crude mortality rates remained stable in all three age groups. Among 
females, although AAPCs in the 40–59-year age group were stable, those in the 60–79-year 
age group and ≥80-year age group showed continuous increases. 
Trends in the age-adjusted NTM mortality rates by age and sex 
The overall trends in age-adjusted NTM mortality rates by sex are shown in Fig. 4, and the 
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results of the joinpoint regression analysis by sex are shown in Table 2. The overall 
age-adjusted NTM mortality rates increased significantly over the study period. 
Comparison of trends in the crude TB-associated and NTM-associated mortality rates 
Fig. 5 shows the comparison of trends in the crude annual mortality rate of TB-associated 
deaths and NTM-associated deaths per 100,000 population, in all age groups combined. 
While the crude TB mortality rate decreased from 4.25/100,000 in 1997 to 2.44/100,000 in 
2016, the crude NTM mortality rate increased from 0.63/100,000 in 1997 to 1.93/100,000 in 
2016. While the crude TB mortality rate decreased in males, it remained higher than the NTM 
mortality rate. Conversely, in females, the crude NTM mortality exceeded the TB mortality 
rate during 2014–2016 and continued to increase. 
Discussion 
This study showed that the absolute number of deaths associated with NTM infections 
increased in Japan between 1997 and 2016; the overall crude annual mortality rate per 
100,000 population increased from 0.63 to 1.93. Notably, our study showed significant 
differences in NTM mortality rates and NTM mortality trends, that is, dramatic increases in 
the number of deaths, especially in the older female population; this persisted even after age 
adjustment. Considering the increase in the aging population worldwide, the high 
NTM-associated mortality rate in the elderly may increase the socioeconomic burden on 
health services. 
Increased NTM-associated mortality rates can be explained by the increased incidence of 
NTM disease in Japan. The number of newly diagnosed cases of NTM-PD has increased, 
with the incidence rate of 14.7 cases per 100,000 person-years in 2014; this increased from 
5.7 cases per 100,000 person-years reported in 2007 [17]. Several factors may be contributing 
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to the increasing incidence of NTM disease, including increased awareness of NTM among 
healthcare practitioners, improved laboratory techniques for NTM identification, changes in 
host factors such as advanced age and various immunocompromising conditions, increased 
pathogenicity in the organisms, and changes in environmental factors [22, 23]. Among them, 
the increasing life-span among individuals of both sexes over the past 20 years is a prominent 
contributor in Japan, where the population aged over 65 years increased from 15.7% of the 
total population in 1997 to 27.3% in 2016. Considering the fact that NTM typically affects 
older individuals [10, 18], an increased number of the aged population must be an important 
contributing factor. Agricultural activities have been associated with NTM transmission [24], 
but we could not assess whether agricultural activities affected NTM mortality rates in this 
study owing to a lack of data. 
In our study, the female population experienced a greater increase in mortality rates than the 
male population over the study period. Differences in NTM disease according to sex have 
varied among studies, but there are several possible explanations for the difference observed 
in the trend. First, a recent large population-based study in Korea reported that the overall 
ratio of female-to-male patients with NTM infection was 1.57, and the incidence of NTM 
infection in 2016 was approximately 2.5-fold higher in females than in males [25]. 
Additionally, it showed an age-adjusted mortality rate ratio of 2.16 among individuals with 
NTM disease relative to the general population [25]. Given these results, it is not surprising 
that in our study, females aged ≥80 years had a higher NTM mortality rate than in other sex 
and age groups in our study. Second, nearly 90% of pulmonary NTM in Japan is caused by 
MAC, and the prevalence of MAC infection occurs predominantly in the female elderly 
population [3]. Although the prognosis of MAC infection is considered to be relatively good, 
a recent systematic review by Diel et al. [26] reported that the 5-year all-cause mortality rate 
among individuals with MAC lung disease was as high as 27%. Third, M. abscessus complex 
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comprises a group of rapidly growing, multidrug-resistant NTM, with a relatively poor 
prognosis compared to other NTM infections [27]. The rate of M. abscessus complex 
infections is high among elderly females [27], and is reported to have increased 
approximately 5-fold from 1 case in 2001 to 5 cases per 1,000,000 person-years in 2014 [17]. 
This increase may have contributed to the increased mortality rate in the elderly female 
population. 
Sex hormones may play an important role in postmenopausal women as a causative factor for 
NTM infection [28]. It is known that low serum estradiol levels are strongly related to MAC 
lung disease in middle-aged or elderly women, and that compared to uninfected controls, 
women with MAC lung disease have lower serum dehydroepiandrosterone sulfate levels [28, 
29]. Chan et al. [30] reported that an abnormal expression of sex hormones, adipokines, 
and/or TGF-beta may explain why women of low weight and older age are more susceptible 
to NTM lung disease. Although these studies suggested that lower levels of sex hormones, 
especially estrogen, may result in an increased occurrence of NTM disease in elderly women, 
further investigation of these hormonal effects on immune function in NTM infection is 
required. 
Despite the current increase in NTM incidence and mortality, the appropriate regimen and 
length of treatment for NTM-PD have not been established [31]. The management of 
NTM-PD is a challenge, as it requires prolonged use of combinations of multiple drugs such 
as macrolides, rifampin, and ethambutol, which have significant potential for toxicity and 
drug-drug interactions [32]. The decision to start treatment must be made based on the 
potential risks and benefits of therapy in individual patients. Based on recent studies [15, 33, 
34], advanced age, male gender, low body mass index (<18.5 kg/m2), underlying respiratory 
diseases (especially chronic pulmonary aspergillosis), particular radiographic findings 
(cavitary or nodular bronchiectasis), malignancy (pulmonary or extrapulmonary), chronic 
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heart or liver disease, anemia, hypoalbuminemia, and an erythrocyte sedimentation rate of 
>50 mm/h are indicators of poor prognosis. Considering these risk factors, the quality of life,
and a patient-centered approach, rather than solely expecting microbiologic eradication [35], 
clinicians should determine whether to initiate treatment. Considering the increasing 
mortality rate in the elderly population, especially in women, decisions regarding the 
initiation and discontinuation of NTM treatment may become more challenging and open to 
question in the future. 
We previously conducted similar research on trends in the incidence and mortality rate of TB 
in Japan from 1997 to 2016 [36]; this showed a decrease in the TB mortality rate over the 
20-year period. Of note, our current study revealed that in females, the crude NTM mortality
rate exceeded the crude TB mortality rate in 2014, 2015, and 2016. These results suggest that 
NTM has become a more serious threat than TB, especially among aged women. Therefore, 
we believe that healthcare and political measures to combat NTM infection should be taken 
urgently in Japan. 
A strength of the present study is that it is the first to use the national database for the purpose 
of trend analysis for NTM-associated mortality in Japan, using joinpoint regression analysis. 
However, the study has several limitations owing to the nature of the data and the methods 
used. First, since the underlying causes of death were analyzed from death certificates, 
NTM-associated death rates may have been underestimated. Second, this study obtained data 
by selecting the causes of death from the nosological classifications provided in ICD-10; thus, 
it was impossible to determine whether the recorded cause of death was accurate. For 
example, the diagnosis of NTM lung disease is made by at least two isolations of an identical 
NTM organism from sputum or a single detection of NTM in invasive examinations, such as 
bronchoscopy or lung biopsy [37]. Thus, the diagnosis of NTM death can be inappropriately 
made and recorded. Finally, owing to the absence of clinical data, we could not determine the 
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infectious foci of NTM, perform in-depth analyses at a species level, or determine the 
prognosis of NTM infections. Moreover, data on comorbidities were not available from the 
death certificate, and the effect of immunocompromised states associated with NTM infection 
may have been underestimated. Since our study did not include ICD-10 code B20.0 (HIV 
disease resulting in mycobacterial infection and HIV disease resulting in tuberculosis), 
NTM-associated deaths related to HIV infection were not included in the analysis. However, 
other immunosuppressive conditions, which may have predisposed patients to NTM 
infections, were not excluded in this study. Despite these limitations, the present study 
evaluated the Japanese national NTM-associated mortality trends over a 20-year period. The 
findings of this study are useful for future policy decision making. 
 
In conclusion, we identified an overall increasing trend of NTM-associated mortality, 
especially among the elderly female population in Japan over a 20-year period. In addition to 
the increasing size of the elderly population, we assume that an increased awareness of the 
disease among clinicians and technical advancements in bacterial identification may have 
contributed to the observed increase in NTM-associated mortality. Given the increased 
mortality and a susceptible aging population, NTM infections warrant greater attention from 
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Figure legends 1 
Fig. 1. Nontuberculous mycobacteria-associated deaths by year and sex, 1997–2016 2 
Fig. 2. Age and sex distribution of nontuberculous mycobacteria-associated deaths, 3 
1997–2016 4 
Fig. 3. Crude nontuberculous mycobacteria-associated annual mortality rate (per 5 
100,000 population) by age and sex, 1997–2016 6 
Fig. 4. Age-adjusted nontuberculous mycobacteria-associated annual mortality rate (per 7 
100,000 population) by sex, 1997–2016 8 
Fig. 5. Comparison of crude tuberculosis and nontuberculous mycobacteria-associated 9 
annual mortality rate, 1997–2016 10 
11 
Supplementary Table 1. Crude nontuberculous mycobacteria-associated annual 12 
mortality rate (per 100,000 population) by age and sex, 1997–2016. 13 
Table 1. Trends in the annual crude mortality rate due to non-tuberculosis 















40–59 1997–2016 −1.1 –1.1 (–3.3 to 1.1)
60–79 1997–2001 7.7 2001–2016 –0.5 1.1 (–0.7 to 3.0) 
≥80 1997–2000 17.9 2000–2016 –0.1 2.5 (–0.5 to 5.6) 
Female 
40–59 1997–2016 1.5 1.5 (–0.9 to 3.9) 
60–79 1997–2016 3.5 * 3.5 (2.8 to 4.3) * 
≥80 1997–2016 4.3 * 4.3 (3.7 to 4.9) * 
* Significantly different from zero (p <0.05) 
Abbreviations: APC, annual percentage change; CI, confidence interval 
Table
Within each sex and age group, periods were separated as Period 1 and Period 2 when 
the trend changes were statistically detected in the Joinpoint regression analysis during 
the study period. 
Table 2. Trends in the age-adjusted nontuberculous mycobacteria-associated 
mortality rate per 100,000 population aged ≥40 years, 1997–2016 







Average APC (%), 
(95% CI) 
Total 1997–2000 10.4 * 2000–2016 1.7 * 3.1 (2.0 to 4.1) * 
Male 1997–2000 11.4 2000–2016 −0.6 1.2 (–0.7 to 3.2) 
Female 1997–1999 16.1 1999–2016 3.3 * 4.6 (2.7 to 6.6) * 
* Significantly different from zero (p <0.05) 
Abbreviations: APC, annual percentage change; CI, confidence interval 
Within each sex and age group, periods were separated as Period 1 and Period 2 when 
the trend changes were statistically detected in the Joinpoint regression analysis during 






Supplementary Table 1. Crude nontuberculous mycobacteria-associated annual mortality rate (per 100,000 population) by age and sex, 1997–2016. 
Age 
(years) 
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
≥40 
Overall 0.63 0.77 0.86 0.92 1.05 1.06 1.16 1.22 1.20 1.27 1.29 1.39 1.41 1.53 1.63 1.68 1.65 1.83 1.82 1.93 
Male 0.61 0.76 0.76 0.95 1.04 0.97 1.02 1.20 1.06 1.16 1.03 1.05 1.15 1.19 1.26 1.33 1.30 1.29 1.33 1.31 
Female 0.65 0.78 0.95 0.90 1.06 1.15 1.29 1.24 1.32 1.37 1.53 1.68 1.63 1.84 1.97 1.99 1.96 2.31 2.26 2.47 
40–59 
Overall 0.08 0.08 0.10 0.09 0.09 0.08 0.09 0.12 0.13 0.11 0.09 0.07 0.10 0.08 0.10 0.09 0.10 0.09 0.09 0.09 
Male 0.08 0.07 0.11 0.12 0.14 0.07 0.09 0.15 0.13 0.15 0.10 0.07 0.08 0.08 0.07 0.10 0.07 0.10 0.09 0.10 
Female 0.08 0.08 0.09 0.06 0.04 0.08 0.09 0.09 0.14 0.07 0.07 0.08 0.12 0.07 0.13 0.08 0.14 0.08 0.09 0.08 
60–79 
Overall 0.91 1.13 1.25 1.16 1.39 1.32 1.44 1.47 1.35 1.52 1.44 1.50 1.35 1.47 1.63 1.47 1.62 1.69 1.68 1.71 
Male 1.02 1.25 1.18 1.30 1.48 1.40 1.40 1.57 1.41 1.48 1.25 1.35 1.21 1.27 1.43 1.27 1.45 1.25 1.48 1.28 
Female 0.83 1.02 1.30 1.04 1.32 1.26 1.48 1.38 1.30 1.55 1.61 1.62 1.47 1.65 1.80 1.66 1.77 2.09 1.86 2.09 
≥80 
Overall 3.80 4.52 4.81 5.87 6.04 6.22 6.48 6.48 6.37 6.22 6.53 6.90 7.12 7.71 7.59 8.32 7.34 8.41 8.24 8.71 
Male 4.41 5.72 5.56 7.82 7.77 7.09 7.38 8.25 6.76 7.19 6.53 6.05 7.42 7.46 7.12 8.33 7.04 7.51 6.79 7.19 
Female 3.50 3.94 4.46 4.94 5.22 5.81 6.06 5.66 6.19 5.75 6.53 7.32 6.96 7.83 7.83 8.32 7.50 8.88 9.02 9.53 
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Background: The incidence of nontuberculous mycobacterial (NTM) infections has been 
increasing worldwide, becoming a significant healthcare burden especially among elderly 
people. This study aimed to evaluate the trends in NTM-associated mortality in Japan. 
Methods: This study used vital statistics data and data on all NTM-associated deaths 
(N=18,814) among individuals aged ≥40 years in Japan from 1997 to 2016. We calculated the 
crude and age-adjusted mortality rates by age and sex and used joinpoint regression to 
analyze trends and estimate the average annual percentage change (AAPC). We compared 
crude NTM- and tuberculosis (TB)-associated mortality rates by sex. 
Results: The overall crude annual mortality rate increased from 0.63/100,000/year in 1997 to 
1.93/100,000/year in 2016 and was the highest among individuals aged 80–84 years. The 
AAPC of the crude mortality rates among males of all ages and females aged 40–59 years 
were stable but increased among females aged 60–79 years (3.5%, 95% confidence interval 
[CI]: 2.8–4.3%) and ≥80 years (4.3%, 95% CI: 3.7–4.9%). Among males, the age-adjusted 
mortality rates did not show a significant trend, while among females, the rates increased 
over the study period (AAPC: 4.6%, 95% CI: 2.7–6.6%). In females, the crude 
NTM-associated mortality rate exceeded the TB mortality rate in 2014, 2015, and 2016. 
Conclusions: NTM mortality increased in Japan between 1997 and 2016, especially among 
the elderly female population. Given the increasing NTM-associated mortality and 




Nontuberculous mycobacteria (NTM) are mycobacteria other than Mycobacterium 
tuberculosis and special auxotrophs such as Mycobacterium leprae, and currently include 
more than 180 species [1]. NTM are ubiquitous environmental bacteria, that are present in 
soil and water sources [2]; among them, Mycobacterium avium complex (MAC), which 
includes M. avium, M. intracellulare, and M. chimaera, is the most common cause of NTM 
diseases worldwide, including Japan [3, 4]. Pathogenic NTM can infect humans as a result of 
ingestion, inhalation, and dermal contact from the environment, causing a wide variety of 
diseases [5]. Although NTM can invade lymph nodes, joints, skin, and soft tissues, they most 
frequently cause pulmonary lesions [5]. NTM pulmonary disease (NTM-PD) has two main 
presentations. The first presentation is a fibrocavitary disease, that occurs in patients with 
pre-existing pulmonary diseases, including chronic obstructive pulmonary disease or 
bronchiectasis. The second manifestation is a nodular bronchiectasis of the lingula and 
middle lobe, that tends to affect middle-aged and elderly women [6, 7]. 
The incidence of NTM infection has been increasing worldwide in recent years. During the 
past decade, the annual NTM disease incidence rates (per 100,000) in developed countries 
were as follows: 0.72–0.74 in France [8], 0.9–2.9 in the United Kingdom [9], 2.7–5.6 in the 
United States [10, 11], and 2.2–3.2 in Australia [12]. The increasing NTM disease incidence 
is placing a significant burden on healthcare systems [13, 14]. In Japan, which has a rapidly 
aging population, the reported incidence rates are higher than those of other developed 
countries. For instance, the annual incidence of NTM-PD in Nagasaki Prefecture was >10.0 
per 100,000 population in 2008–2009 [15]. A large, laboratory-based study that used data 
from 4,710 Japanese institutions, revealed that the incidence rate of NTM-PD was 24.0 per 
100,000 population in 2012–2013 [3]. Additionally, a national cross-sectional study based on 
health insurance claims data revealed an incidence rate of NTM-PD of 29.0 per 100,000 
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population in Japan in 2011, which was among the highest worldwide [16]. Another study, 
that included 551 medical facilities certified by the Japanese Respiratory Society, revealed an 
NTM-PD incidence rate of 14.7 per 100,000 population in Japan in 2014; this was a 2.6-fold 
increase since 2007 [17]. 
Elderly people are more susceptible to NTM disease, and advanced age is an important risk 
factor [10, 18]. Since Japan has one of the most rapidly aging populations in the world, it is 
possible that the mortality rate owing to NTM disease has been increasing. Although 
evaluating longitudinal national trends in NTM-associated mortality rates is essential for 
effective health policy administration, there have been no previous reports on the long-term 
trends in NTM-associated mortality rates in Japan. This study, therefore, aimed to examine 
current trends in NTM-associated mortality. 
Materials and methods 
Data source 
Death certificates in Japan are comprehensively collected and saved as computerized files 
after being completed by medical doctors. The data files including patient’s basic information 
are publicly available after anonymization. We examined the Japanese Vital Statistics data 
from 1997 to 2016, collected by the Japanese Ministry of Health, Labour and Welfare, which 
uses the International Classification of Diseases, 10th revision (ICD-10) to code the 
underlying causes of death [19]. NTM-associated mortality was defined using the ICD-10 
codes A31 (A31.0, A31.1, A31.8, and A31.9), namely, “infection due to other mycobacteria,” 
based on previous studies [20, 21]. Data on NTM-associated mortality analyzed in the present 
study were those recorded as the underlying cause of death in the death certificate, as 
performed in the previous study [21]. Data of patients aged ≥40 years were stratified by age 
and sex to calculate crude and age-adjusted mortality rates per 100,000 population. The age 
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was categorized as follows: 40–59 years, 60–79 years, and ≥80 years. All patients aged <40 
years were excluded from the analysis owing to the small number of deaths in this age 
category. For comparison, we also examined tuberculosis (TB)-associated deaths among 
patients aged ≥40 years during the same period as the underlying cause of death (ICD–10 
codes A15–A19). 
Statistical analyses and data processing 
To estimate the trends in crude and age-adjusted mortality rates, a joinpoint regression model 
was applied using the Joinpoint Regression Program, version 4.7.0.0, February 2019 
(Statistical Research and Applications Branch, National Cancer Institute, USA). The annual 
percentage changes (APCs) between trend-change points were determined with 95% 
confidence intervals (CI). We used the direct age-standardization method to calculate 
age-adjusted rates of NTM-associated mortality using the Japanese population in 1997 as the 
standard population, expressed per 100,000 population, with 5-year age groups. To compare 
differences in mortality trends among population subgroups, we estimated the average annual 
percentage change (AAPC) for the entire period. A p-value <0.05 was defined as the level at 
which the slope was statistically significantly different from zero. 
Ethics approval 
This study used data published by the Japanese Ministry of Health, Labour and Welfare and 
the Statistics Bureau of the Ministry of Internal Affairs and Communications. Ethics approval 
was obtained by the institutional review board of Okayama University Hospital (No. 
1910-009). The requirement for informed consent was waived, as the study was a 
retrospective analysis of routinely collected data. 
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Results 
Number of NTM-associated deaths 
In total, 18,791 NTM-associated deaths occurred over the 20-year study period. The annual 
number of deaths by sex is shown in Fig. 1. During the study period, the total number of 
deaths per year increased from 402 in 1997 to 1,487 in 2016. Although the number of 
NTM-associated deaths among males and females was similar in 1997 (183 and 219, 
respectively), the number of deaths among females were approximately double that of males 
in 2016 (478 and 1,009, respectively). The numbers of NTM-associated deaths by 5-year age 
groups are shown in Fig. 2. The number of NTM-associated deaths increased from 45 years 
of age, reaching its peak in both sexes in the 80–84-year age group. 
Trends in the crude NTM mortality rates by age and sex 
Fig. 3 summarizes the crude mortality rates of NTM-associated deaths among patients aged 
≥40 years, by 20-year age groups and sex. The detailed results for each age group are 
provided in Supplementary Table 1. The overall crude annual mortality rate per 100,000 
population increased from 0.63 in 1997 to 1.93 in 2016. The crude mortality rates were 
higher in both sexes of the older age groups. The results of the joinpoint regression analysis 
of the crude mortality rates by 20-year age groups are shown in Table 1. In males, AAPCs for 
the entire period of the crude mortality rates remained stable in all three age groups. Among 
females, although AAPCs in the 40–59-year age group were stable, those in the 60–79-year 
age group and ≥80-year age group showed continuous increases. 
Trends in the age-adjusted NTM mortality rates by age and sex 
The overall trends in age-adjusted NTM mortality rates by sex are shown in Fig. 4, and the 
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results of the joinpoint regression analysis by sex are shown in Table 2. The overall 
age-adjusted NTM mortality rates increased significantly over the study period. 
Comparison of trends in the crude TB-associated and NTM-associated mortality rates 
Fig. 5 shows the comparison of trends in the crude annual mortality rate of TB-associated 
deaths and NTM-associated deaths per 100,000 population, in all age groups combined. 
While the crude TB mortality rate decreased from 4.25/100,000 in 1997 to 2.44/100,000 in 
2016, the crude NTM mortality rate increased from 0.63/100,000 in 1997 to 1.93/100,000 in 
2016. While the crude TB mortality rate decreased in males, it remained higher than the NTM 
mortality rate. Conversely, in females, the crude NTM mortality exceeded the TB mortality 
rate during 2014–2016 and continued to increase. 
Discussion 
This study showed that the absolute number of deaths associated with NTM infections 
increased in Japan between 1997 and 2016; the overall crude annual mortality rate per 
100,000 population increased from 0.63 to 1.93. Notably, our study showed significant 
differences in NTM mortality rates and NTM mortality trends, that is, dramatic increases in 
the number of deaths, especially in the older female population; this persisted even after age 
adjustment. Considering the increase in the aging population worldwide, the high 
NTM-associated mortality rate in the elderly may increase the socioeconomic burden on 
health services. 
Increased NTM-associated mortality rates can be explained by the increased incidence of 
NTM disease in Japan. The number of newly diagnosed cases of NTM-PD has increased, 
with the incidence rate of 14.7 cases per 100,000 person-years in 2014; this increased from 
5.7 cases per 100,000 person-years reported in 2007 [17]. Several factors may be contributing 
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to the increasing incidence of NTM disease, including increased awareness of NTM among 
healthcare practitioners, improved laboratory techniques for NTM identification, changes in 
host factors such as advanced age and various immunocompromising conditions, increased 
pathogenicity in the organisms, and changes in environmental factors [22, 23]. Among them, 
the increasing life-span among individuals of both sexes over the past 20 years is a prominent 
contributor in Japan, where the population aged over 65 years increased from 15.7% of the 
total population in 1997 to 27.3% in 2016. Considering the fact that NTM typically affects 
older individuals [10, 18], an increased number of the aged population must be an important 
contributing factor. Agricultural activities have been associated with NTM transmission [24], 
but we could not assess whether agricultural activities affected NTM mortality rates in this 
study owing to a lack of data. 
In our study, the female population experienced a greater increase in mortality rates than the 
male population over the study period. Differences in NTM disease according to sex have 
varied among studies, but there are several possible explanations for the difference observed 
in the trend. First, a recent large population-based study in Korea reported that the overall 
ratio of female-to-male patients with NTM infection was 1.57, and the incidence of NTM 
infection in 2016 was approximately 2.5-fold higher in females than in males [25]. 
Additionally, it showed an age-adjusted mortality rate ratio of 2.16 among individuals with 
NTM disease relative to the general population [25]. Given these results, it is not surprising 
that in our study, females aged ≥80 years had a higher NTM mortality rate than in other sex 
and age groups in our study. Second, nearly 90% of pulmonary NTM in Japan is caused by 
MAC, and the prevalence of MAC infection occurs predominantly in the female elderly 
population [3]. Although the prognosis of MAC infection is considered to be relatively good, 
a recent systematic review by Diel et al. [26] reported that the 5-year all-cause mortality rate 
among individuals with MAC lung disease was as high as 27%. Third, M. abscessus complex 
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comprises a group of rapidly growing, multidrug-resistant NTM, with a relatively poor 
prognosis compared to other NTM infections [27]. The rate of M. abscessus complex 
infections is high among elderly females [27], and is reported to have increased 
approximately 5-fold from 1 case in 2001 to 5 cases per 1,000,000 person-years in 2014 [17]. 
This increase may have contributed to the increased mortality rate in the elderly female 
population. 
Sex hormones may play an important role in postmenopausal women as a causative factor for 
NTM infection [28]. It is known that low serum estradiol levels are strongly related to MAC 
lung disease in middle-aged or elderly women, and that compared to uninfected controls, 
women with MAC lung disease have lower serum dehydroepiandrosterone sulfate levels [28, 
29]. Chan et al. [30] reported that an abnormal expression of sex hormones, adipokines, 
and/or TGF-beta may explain why women of low weight and older age are more susceptible 
to NTM lung disease. Although these studies suggested that lower levels of sex hormones, 
especially estrogen, may result in an increased occurrence of NTM disease in elderly women, 
further investigation of these hormonal effects on immune function in NTM infection is 
required. 
Despite the current increase in NTM incidence and mortality, the appropriate regimen and 
length of treatment for NTM-PD have not been established [31]. The management of 
NTM-PD is a challenge, as it requires prolonged use of combinations of multiple drugs such 
as macrolides, rifampin, and ethambutol, which have significant potential for toxicity and 
drug-drug interactions [32]. The decision to start treatment must be made based on the 
potential risks and benefits of therapy in individual patients. Based on recent studies [15, 33, 
34], advanced age, male gender, low body mass index (<18.5 kg/m2), underlying respiratory 
diseases (especially chronic pulmonary aspergillosis), particular radiographic findings 
(cavitary or nodular bronchiectasis), malignancy (pulmonary or extrapulmonary), chronic 
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heart or liver disease, anemia, hypoalbuminemia, and an erythrocyte sedimentation rate of 
>50 mm/h are indicators of poor prognosis. Considering these risk factors, the quality of life, 
and a patient-centered approach, rather than solely expecting microbiologic eradication [35], 
clinicians should determine whether to initiate treatment. Considering the increasing 
mortality rate in the elderly population, especially in women, decisions regarding the 
initiation and discontinuation of NTM treatment may become more challenging and open to 
question in the future. 
We previously conducted similar research on trends in the incidence and mortality rate of TB 
in Japan from 1997 to 2016 [36]; this showed a decrease in the TB mortality rate over the 
20-year period. Of note, our current study revealed that in females, the crude NTM mortality 
rate exceeded the crude TB mortality rate in 2014, 2015, and 2016. These results suggest that 
NTM has become a more serious threat than TB, especially among aged women. Therefore, 
we believe that healthcare and political measures to combat NTM infection should be taken 
urgently in Japan. 
A strength of the present study is that it is the first to use the national database for the purpose 
of trend analysis for NTM-associated mortality in Japan, using joinpoint regression analysis. 
However, the study has several limitations owing to the nature of the data and the methods 
used. First, since the underlying causes of death were analyzed from death certificates, 
NTM-associated death rates may have been underestimated. Second, this study obtained data 
by selecting the causes of death from the nosological classifications provided in ICD-10; thus, 
it was impossible to determine whether the recorded cause of death was accurate. For 
example, the diagnosis of NTM lung disease is made by at least two isolations of an identical 
NTM organism from sputum or a single detection of NTM in invasive examinations, such as 
bronchoscopy or lung biopsy [37]. Thus, the diagnosis of NTM death can be inappropriately 
made and recorded. Finally, owing to the absence of clinical data, we could not determine the 
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infectious foci of NTM, perform in-depth analyses at a species level, or determine the 
prognosis of NTM infections. Moreover, data on comorbidities were not available from the 
death certificate, and the effect of immunocompromised states associated with NTM infection 
may have been underestimated. Since our study did not include ICD-10 code B20.0 (HIV 
disease resulting in mycobacterial infection and HIV disease resulting in tuberculosis), 
NTM-associated deaths related to HIV infection were not included in the analysis. However, 
other immunosuppressive conditions, which may have predisposed patients to NTM 
infections, were not excluded in this study. Despite these limitations, the present study 
evaluated the Japanese national NTM-associated mortality trends over a 20-year period. The 
findings of this study are useful for future policy decision making. 
In conclusion, we identified an overall increasing trend of NTM-associated mortality, 
especially among the elderly female population in Japan over a 20-year period. In addition to 
the increasing size of the elderly population, we assume that an increased awareness of the 
disease among clinicians and technical advancements in bacterial identification may have 
contributed to the observed increase in NTM-associated mortality. Given the increased 
mortality and a susceptible aging population, NTM infections warrant greater attention from 





We would like to thank Editage (www.editage.jp) for English language editing. 
13 
 
Conflicts of interest 




1. Kwon YS, Koh WJ, Daley CL. Treatment of Mycobacterium avium Complex 
Pulmonary Disease. Tuberc Respir Dis (Seoul) 2019; 82: 15-26. 
2. Falkinham JO, 3rd. Surrounded by mycobacteria: nontuberculous mycobacteria in the 
human environment. J Appl Microbiol 2009; 107: 356-367. 
3. Morimoto K, Hasegawa N, Izumi K, et al. A Laboratory-based Analysis of 
Nontuberculous Mycobacterial Lung Disease in Japan from 2012 to 2013. Ann Am 
Thorac Soc 2017; 14: 49-56. 
4. Daley CL. Mycobacterium avium Complex Disease. Microbiol Spectr 2017; 5. 
5. Nishiuchi Y, Iwamoto T, Maruyama F. Infection Sources of a Common 
Non-tuberculous Mycobacterial Pathogen, Mycobacterium avium Complex. Front 
Med (Lausanne) 2017; 4: 27. 
6. Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous 
mycobacteria. Int J Infect Dis 2016; 45: 123-134. 
7. van Ingen J, Aksamit T, Andrejak C, et al. Treatment outcome definitions in 
nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. 
Eur Respir J 2018; 51. 
8. Dailloux M, Abalain ML, Laurain C, et al. Respiratory infections associated with 
nontuberculous mycobacteria in non-HIV patients. Eur Respir J 2006; 28: 1211-1215. 
9. Moore JE, Kruijshaar ME, Ormerod LP, Drobniewski F, Abubakar I. Increasing 
reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 
1995-2006. BMC Public Health 2010; 10: 612. 
10. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of 
nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J 
15 
Respir Crit Care Med 2012; 185: 881-886. 
11. Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL. Nontuberculous 
mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin 
Infect Dis 2009; 49: e124-129. 
12. Thomson RM, Centre NTMwgaQTC, Queensland Mycobacterial Reference L. 
Changing epidemiology of pulmonary nontuberculous mycobacteria infections. 
Emerg Infect Dis 2010; 16: 1576-1583. 
13. Strollo SE, Adjemian J, Adjemian MK, Prevots DR. The Burden of Pulmonary 
Nontuberculous Mycobacterial Disease in the United States. Ann Am Thorac Soc 
2015; 12: 1458-1464. 
14. Thomson R, Donnan E, Unwin S. Nontuberculous Mycobacterial Lung Disease. Time 
to Get a Grip! Ann Am Thorac Soc 2015; 12: 1425-1427. 
15. Ide S, Nakamura S, Yamamoto Y, et al. Epidemiology and clinical features of 
pulmonary nontuberculous mycobacteriosis in Nagasaki, Japan. PLoS One 2015; 10: 
e0128304. 
16. Izumi K, Morimoto K, Hasegawa N, et al. Epidemiology of Adults and Children 
Treated for Nontuberculous Mycobacterial Pulmonary Disease in Japan. Ann Am 
Thorac Soc 2019; 16: 341-347. 
17. Namkoong H, Kurashima A, Morimoto K, et al. Epidemiology of Pulmonary 
Nontuberculous Mycobacterial Disease, Japan. Emerg Infect Dis 2016; 22: 
1116-1117. 
18. Andrejak C, Thomsen VO, Johansen IS, et al. Nontuberculous pulmonary 
mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care 
Med 2010; 181: 514-521. 
19. Japanese Ministry of Health LaW. Vital statistics of Japan. Available at: 
16 
https://www.mhlw.go.jp/english/database/db-hw/vs01.html. Accessed 31 July 2019. 
20. Vinnard C, Longworth S, Mezochow A, Patrawalla A, Kreiswirth BN, Hamilton K. 
Deaths Related to Nontuberculous Mycobacterial Infections in the United States, 
1999-2014. Ann Am Thorac Soc 2016; 13: 1951-1955. 
21. Mirsaeidi M, Machado RF, Garcia JG, Schraufnagel DE. Nontuberculous 
mycobacterial disease mortality in the United States, 1999-2010: a population-based 
comparative study. PLoS One 2014; 9: e91879. 
22. Marras TK, Daley CL. Epidemiology of human pulmonary infection with 
nontuberculous mycobacteria. Clin Chest Med 2002; 23: 553-567. 
23. Morimoto K, Iwai K, Uchimura K, et al. A steady increase in nontuberculous 
mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thorac Soc 
2014; 11: 1-8. 
24. Chou MP, Clements AC, Thomson RM. A spatial epidemiological analysis of 
nontuberculous mycobacterial infections in Queensland, Australia. BMC Infect Dis 
2014; 14: 279. 
25. Park SC, Kang MJ, Han CH, et al. Prevalence, incidence, and mortality of 
nontuberculous mycobacterial infection in Korea: a nationwide population-based 
study. BMC Pulm Med 2019; 19: 140. 
26. Diel R, Lipman M, Hoefsloot W. High mortality in patients with Mycobacterium 
avium complex lung disease: a systematic review. BMC Infect Dis 2018; 18: 206. 
27. Koh WJ, Jeong BH, Kim SY, et al. Mycobacterial Characteristics and Treatment 
Outcomes in Mycobacterium abscessus Lung Disease. Clin Infect Dis 2017; 64: 
309-316. 
28. Uwamino Y, Nishimura T, Sato Y, et al. Low serum estradiol levels are related to 
Mycobacterium avium complex lung disease: a cross-sectional study. BMC Infect Dis 
17 
2019; 19: 1055. 
29. Danley J, Kwait R, Peterson DD, et al. Normal estrogen, but low
dehydroepiandrosterone levels, in women with pulmonary Mycobacterium avium
complex. A preliminary study. Ann Am Thorac Soc 2014; 11: 908-914.
30. Chan ED, Iseman MD. Slender, older women appear to be more susceptible to
nontuberculous mycobacterial lung disease. Gend Med 2010; 7: 5-18.
31. Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the
management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).
Thorax 2017; 72: ii1-ii64.
32. Ryu YJ, Koh WJ, Daley CL. Diagnosis and Treatment of Nontuberculous
Mycobacterial Lung Disease: Clinicians' Perspectives. Tuberc Respir Dis (Seoul)
2016; 79: 74-84.
33. Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y.
Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex
lung disease. Am J Respir Crit Care Med 2012; 185: 575-583.
34. Jhun BW, Moon SM, Jeon K, et al. Prognostic factors associated with long-term
mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a
15-year follow-up study. Eur Respir J 2019.
35. Czaja CA, Levin AR, Cox CW, Vargas D, Daley CL, Cott GR. Improvement in
Quality of Life after Therapy for Mycobacterium abscessus Group Lung Infection. A
Prospective Cohort Study. Ann Am Thorac Soc 2016; 13: 40-48.
36. Hagiya H, Koyama T, Zamami Y, et al. Trends in incidence and mortality of
tuberculosis in Japan: a population-based study, 1997-2016. Epidemiol Infect 2018:
1-10.
37. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement:
18 
diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J 
Respir Crit Care Med 2007; 175: 367-416. 
Harada et al. 
NTM 
19 
Figure legends 1 
Fig. 1. Nontuberculous mycobacteria-associated deaths by year and sex, 1997–2016 2 
Fig. 2. Age and sex distribution of nontuberculous mycobacteria-associated deaths, 3 
1997–2016 4 
Fig. 3. Crude nontuberculous mycobacteria-associated annual mortality rate (per 5 
100,000 population) by age and sex, 1997–2016 6 
Fig. 4. Age-adjusted nontuberculous mycobacteria-associated annual mortality rate (per 7 
100,000 population) by sex, 1997–2016 8 
Fig. 5. Comparison of crude tuberculosis and nontuberculous mycobacteria-associated 9 
annual mortality rate, 1997–2016 10 
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Supplementary Table 1. Crude nontuberculous mycobacteria-associated annual 12 
mortality rate (per 100,000 population) by age and sex, 1997–2016. 13 
